Pancreatic carcinoma usually presents at an incurable stage. The precursor is the pancreatic intraepithelial neoplasm (PanIN), occurring in up to 60 percent of the older population. Only a small subset is histologically advanced and progresses to invasive cancer. Invasion induces an exuberant host: tumor interaction that remains poorly understood, but is likely to have fundament influences on tumor biology and distant host organs. Therefore, pancreatic carcinogenesis is now understood as a progression of intraepithelial neoplasia and as an interaction of cellular compartments. During the past seven years of this SPORE project, we defined a progression of alterations in the K-ras, p16, DPC4/SMAD4, Her2/neu, and BRCA2 genes in the precursor lesions. Variant tumor types were re-interpreted within this tumorigenic model and we comprehensively profiled gene expression through SAGE analysis. A progression model of neoplasia was constructed, contributing to a new consensus classification system for PanIN lesions. Our long-term goal is to identify the fundamental genetic alterations and patterns of gene expression in the progression of precursor lesions to invasive carcinoma, in order to guide diagnosis and therapy. In the proposed grant period, we will: 1) Determine the frequencies and relative timing of genetic and other alterations along the histologic stages of PanIN. We will apply techniques that have proven efficient in this effort, including the microdissection of lesions for genetic analysis and the use of immunohistochemistry. 2) Construct SAGE profiles of pancreatic cancer cell lines and primary tumors. This is the foundation for identification of stage- and tissue-specific markers and insights into host: tumor interactions. 3) Delineate the architectural compartments of gene expression in the host:tumor interaction. Genes identified in Aim 2 are parsed into cellular compartments using in situ and experimental techniques. 4) Develop the new markers in expanded translational settings, such as difficult biopsies, studies applied to Aim 1, variant tumor types, and serum.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA062924-09
Application #
6670282
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-07-01
Project End
2007-06-30
Budget Start
Budget End
Support Year
9
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Staedtke, Verena; Bai, Ren-Yuan; Kim, Kibem et al. (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273-277
Deng, Yang; Tu, Huakang; Pierzynski, Jeanne A et al. (2018) Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 92:20-32
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Chung, Liam; Thiele Orberg, Erik; Geis, Abby L et al. (2018) Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe 23:203-214.e5
Nakamura, Hideki; Lee, Albert A; Afshar, Ali Sobhi et al. (2018) Intracellular production of hydrogels and synthetic RNA granules by multivalent molecular interactions. Nat Mater 17:79-89
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Cruz-Correa, Marcia; Hylind, Linda M; Marrero, Jessica Hernandez et al. (2018) Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology 155:668-673
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58

Showing the most recent 10 out of 883 publications